硬膜内递送靶向脑膜淋巴管的病毒样颗粒疫苗激活抗胶质瘤免疫
该研究开发了基于病毒样颗粒(VLP)的纳米疫苗OVA-HBc,并在原位GL261-OVA-Luc胶质瘤小鼠模型中比较硬膜内、静脉和鼻内递送途径。结果显示仅硬膜内给药诱导显著肿瘤消退并延长生存(60天生存率超过60%),可能与精准靶向脑膜及经脑膜淋巴管(MLVs)引流抗原有关。
要点
- 硬膜内递送OVA-HBc VLP疫苗可诱导胶质瘤小鼠肿瘤消退并延长生存。
- 该效应可能与靶向脑膜淋巴管并促进抗原引流有关。
- 其他给药途径(静脉、鼻内)未显示同等效果。
核心结论
- 硬膜内递送HBc病毒样颗粒可经脑膜淋巴管激活抗胶质瘤免疫,为胶质母细胞瘤免疫治疗提供初步框架。
研究设计与样本
- 研究构建并表征了病毒样颗粒纳米疫苗OVA-HBc,并在原位GL261-OVA-Luc胶质瘤小鼠模型中比较硬膜内、静脉和鼻内递送途径,通过肿瘤成像和生存分析评估疗效。
主要发现
- OVA-HBc形成约36 nm的稳定纳米颗粒,无毒性,并在体外有效激活树突状细胞。
- 体内仅硬膜内递送OVA-HBc诱导显著肿瘤消退,并延长生存(60天生存率超过60%)。
- 该效应可能由精准靶向脑膜及经脑膜淋巴管高效引流抗原介导。
临床怎么用
- 该策略为胶质母细胞瘤免疫治疗提供潜在新途径,但尚处于小鼠模型临床前阶段。
局限性
- 研究仅在小鼠模型中进行,尚未在人体验证。
- 样本量及具体统计数值未在摘要中报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Glioblastoma (GBM) is a lethal brain tumor with a poor prognosis, largely due to an immunosuppressive microenvironment and the blood-brain barrier. The discovery of meningeal lymphatic vessels (MLVs) offers a new avenue for central nervous system immune engagement. OBJECTIVE: We aimed to develop a novel immunotherapy by combining a virus-like particle (VLP) nanovaccine with intradural administration to activate meningeal immunity against GBM. METHODS: A virus-like particle (VLP)-based nanovaccine (OVA-HBc) was engineered and characterized. Its efficacy was evaluated in an orthotopic GL261-OVA-Luc glioma mouse model, comparing intradural delivery with intravenous and intranasal routes through tumor imaging and survival analysis. RESULTS: OVA-HBc formed stable nanoparticles (~ 36 nm), was non-toxic, and potently activated dendritic cells in vitro. In vivo, only intradural administration of OVA-HBc induced marked tumor regression and was associated with prolonged survival (over 60% survival at 60 days), showing potential advantages over systemic routes. This effect is likely mediated by precise meningeal targeting and efficient antigen drainage via MLVs. CONCLUSION: This study suggests that intradural delivery of HBc VLPs can engage MLVs to activate anti-glioma immunity in a mouse model. This approach offers a potential strategy to bypass certain central delivery barriers, representing a preliminary framework for GBM immunotherapy.
引用
- Li M, Zhu J, Huang R, et al. Virus-like particle vaccine targeting meningeal lymphatic vessels via intradural delivery activates anti-glioma immunity. J Neurooncol. 2026. PMID: 42101546. doi:10.1007/s11060-026-05559-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。